Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation

Federal Preemption Update: March 2009 Supreme Court Decision

Free Case Evaluation

Growing Number Of NuvaRing Lawsuits Results In Cases Being Centralized By Courts

Federal Court Has Established NuvaRing Multidistrict Litigation (MDL) And New Jersey State Court Has Designated NuvaRing As A Mass Tort

UPDATE950 NuvaRing Lawsuits Pending As Of December 31, 2011 According To Merck Annual Report

As of December 31, 2011 there were approximately 950 NuvaRing cases filed against Merck and Organon. Of these cases, approximately 820 are or will be pending in the NuvaRing MDL in the U.S. District Court for the Eastern District of Missouri before Judge Rodney Sippel, and approximately 125 are pending in coordinated discovery proceedings in the Bergen County Superior Court of New Jersey before Judge Brian R. Martinotti.



On August 22, 2008 the Judicial Panel on Multidistrict Litigation (JPML) -- acting upon a petition filed by several NuvaRing case plaintiffs -- issued the Transfer Order which created the case captioned In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML.

By means of this ruling, all pending NuvaRing cases and all future NuvaRing lawsuits filed in the federal court system will be centralized for discovery purposes in the Eastern District of Missouri, with Judge Rodney W. Sippel presiding over this NuvaRing multidistrict litigation (MDL).

On March 10, 2009, all NuvaRing personal injury and wrongful death cases filed in the New Jersey state court system were designated as a "mass tort" by the New Jersey Supreme Court. These NuvaRing lawsuits were assigned to Judge Jonathan N. Harris in Bergen County, NJ, for centralized case management.

From the New Jersey Judiciary Mass Tort - NuvaRing web page:

NuvaRing® is a birth control product approved by the FDA for use in the United States in October 2001. It is marketed, labeled and sold in the United States by the Organon USA Inc., a New Jersey corporation with its principal place of business in Roseland, New Jersey and Organon International, Inc., headquartered in the Netherlands. Its parent company, Schering-Plough Corp., is located in Kenilworth New Jersey. NuvaRing® releases two synthetic hormones, etonogestral (a progestin) and ethinyl estradiol (an estrogen) into a woman's body through placement of the contraceptive ring into the vagina. The product is intended to prevent ovulation and minimize sperm penetration.

The complaints filed allege that the plaintiffs suffered damages attendant to the use of this contraceptive. The complaints allege that the use of this drug carries a potential for blood clots due to the extremely high amounts of hormones released. This can lead to death, the breakdown of tissue and organs necessitating, in some cases, amputation, heart attacks and ischemic strokes....


As of June 2009 no NuvaRing case has yet to go to trial in the federal court MDL nor in the NJ state court consolidation.

Go to Free NuvaRing Case Evaluation form >>

Read more on the NuvaRing Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer